PanGen Biotech Inc (KQ:222110) — Market Cap & Net Worth
Market Cap & Net Worth: PanGen Biotech Inc (222110)
PanGen Biotech Inc (KQ:222110) has a market capitalization of $45.36 Million (₩66.93 Billion) as of August 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22212 globally and #1358 in its home market, demonstrating a 3.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PanGen Biotech Inc's stock price ₩4960.00 by its total outstanding shares 13494197 (13.49 Million). See how much does PanGen Biotech Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
PanGen Biotech Inc Market Cap History: 2016 to 2026
PanGen Biotech Inc's market capitalization history from 2016 to 2026. Data shows change from $152.26 Million to $45.36 Million (-13.45% CAGR).
Index Memberships
PanGen Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.02% | #642 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.02% | #642 of 1384 |
Weight: PanGen Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PanGen Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PanGen Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
PanGen Biotech Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.06x
PanGen Biotech Inc's market cap is 0.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $152.26 Million | $1.46 Billion | -$5.13 Billion | 0.10x | N/A |
| 2017 | $135.34 Million | $2.37 Billion | -$7.02 Billion | 0.06x | N/A |
| 2018 | $96.02 Million | $5.68 Billion | -$4.63 Billion | 0.02x | N/A |
| 2019 | $71.06 Million | $2.88 Billion | -$8.94 Billion | 0.02x | N/A |
| 2020 | $92.82 Million | $6.19 Billion | -$4.36 Billion | 0.01x | N/A |
| 2021 | $85.50 Million | $7.94 Billion | -$3.31 Billion | 0.01x | N/A |
| 2022 | $59.44 Million | $6.50 Billion | -$4.49 Billion | 0.01x | N/A |
| 2023 | $62.92 Million | $7.32 Billion | -$4.49 Billion | 0.01x | N/A |
| 2024 | $52.13 Million | $14.67 Billion | $943.69 Million | 0.00x | 0.06x |
Competitor Companies of 222110 by Market Capitalization
Companies near PanGen Biotech Inc in the global market cap rankings as of August 4, 2026.
Key companies related to PanGen Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
PanGen Biotech Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, PanGen Biotech Inc's market cap moved from $152.26 Million to $ 45.36 Million, with a yearly change of -13.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩45.36 Million | -11.43% |
| 2025 | ₩51.21 Million | -1.75% |
| 2024 | ₩52.13 Million | -17.15% |
| 2023 | ₩62.92 Million | +5.85% |
| 2022 | ₩59.44 Million | -30.48% |
| 2021 | ₩85.50 Million | -7.88% |
| 2020 | ₩92.82 Million | +30.63% |
| 2019 | ₩71.06 Million | -26.00% |
| 2018 | ₩96.02 Million | -29.05% |
| 2017 | ₩135.34 Million | -11.11% |
| 2016 | ₩152.26 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of PanGen Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.36 Million USD |
| MoneyControl | $45.36 Million USD |
| MarketWatch | $45.36 Million USD |
| marketcap.company | $45.36 Million USD |
| Reuters | $45.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more